[go: up one dir, main page]

NO20081631L - Lav hygroskopisk Aripiprazol medikament forbindelse og fremgangsmate for fremstilling derav - Google Patents

Lav hygroskopisk Aripiprazol medikament forbindelse og fremgangsmate for fremstilling derav

Info

Publication number
NO20081631L
NO20081631L NO20081631A NO20081631A NO20081631L NO 20081631 L NO20081631 L NO 20081631L NO 20081631 A NO20081631 A NO 20081631A NO 20081631 A NO20081631 A NO 20081631A NO 20081631 L NO20081631 L NO 20081631L
Authority
NO
Norway
Prior art keywords
preparation
drug compound
aripiprazole drug
hygroscopic aripiprazole
make hygroscopic
Prior art date
Application number
NO20081631A
Other languages
English (en)
Other versions
NO336263B1 (no
Inventor
Michiaki Tominaga
Takuji Bando
Satoshi Aoki
Junichi Kawasaki
Makoto Ishigami
Youichi Taniguchi
Tsuyoshi Yabuuchi
Kiyoshi Fujimoto
Yoshihiro Nishioka
Noriyuki Kobayashi
Tsutomo Fujimura
Masanori Takahashi
Kaoru Abe
Tomonori Nakagawa
Koichi Shinhama
Naoto Utsumi
Yoshihiro Oi
Shohei Yamada
Kenji Tomikawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27171631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081631(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en
Publication of NO20081631L publication Critical patent/NO20081631L/no
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NO336263B1 publication Critical patent/NO336263B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer lav-hygroskopiske former av Aripiprazol og prosesser for fremstilling derav, som ikke omdannes til et hydrat eller taper deres opprinnelige oppløselighet selv når et medisinsk preparat inneholdende Aripiprazolanhydrid-krystallene blir lagret i en forlenget periode.
NO20081631A 2001-09-25 2008-04-02 Vannfrie aripiprazol-krystaller E, fremgangsmåte for fremstilling derav, samt farmasøytisk preparat NO336263B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001290645 2001-09-25
JP2001348276 2001-11-14
CA 2379005 CA2379005A1 (en) 2001-09-25 2002-03-27 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
PCT/JP2002/009858 WO2003026659A1 (en) 2001-09-25 2002-09-25 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
NO20081631L true NO20081631L (no) 2003-01-17
NO336263B1 NO336263B1 (no) 2015-07-06

Family

ID=27171631

Family Applications (7)

Application Number Title Priority Date Filing Date
NO20030247A NO328134B1 (no) 2001-09-25 2003-01-17 Vannfrie aripiprazol krystaller B og hydrat A av aripiprazol samt fremgangsmater for fremstilling og anvendelse derav, samt farmsoytisk preparat.
NO20081631A NO336263B1 (no) 2001-09-25 2008-04-02 Vannfrie aripiprazol-krystaller E, fremgangsmåte for fremstilling derav, samt farmasøytisk preparat
NO20081632A NO336262B1 (no) 2001-09-25 2008-04-02 Vannfrie aripiprazol-krystaller F, fremgangsmåte for fremstilling derav samt farmasøytisk preparat
NO20081626A NO336264B1 (no) 2001-09-25 2008-04-02 Vannfrie aripiprazol-krystaller C, fremgangsmåte for fremstilling derav samt farmasøytisk preparat
NO20081627A NO336265B1 (no) 2001-09-25 2008-04-02 Vannfrie aripiprazol-krystaller D, fremgangsmåte for fremstilling derav, samt farmasøytisk preparat
NO20081633A NO20081633L (no) 2001-09-25 2008-04-02 Lav hygroskopisk Aripiprazol medikament forbindelse og fremgangsmate for fremstilling derav
NO20091689A NO336679B1 (no) 2001-09-25 2009-04-28 Fremgangsmåte for fremstilling av et fast oralt preparat av granuler, fremgangsmåte for fremstilling av et fast oral preparat, og farmasøytisk fast oralt preparat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20030247A NO328134B1 (no) 2001-09-25 2003-01-17 Vannfrie aripiprazol krystaller B og hydrat A av aripiprazol samt fremgangsmater for fremstilling og anvendelse derav, samt farmsoytisk preparat.

Family Applications After (5)

Application Number Title Priority Date Filing Date
NO20081632A NO336262B1 (no) 2001-09-25 2008-04-02 Vannfrie aripiprazol-krystaller F, fremgangsmåte for fremstilling derav samt farmasøytisk preparat
NO20081626A NO336264B1 (no) 2001-09-25 2008-04-02 Vannfrie aripiprazol-krystaller C, fremgangsmåte for fremstilling derav samt farmasøytisk preparat
NO20081627A NO336265B1 (no) 2001-09-25 2008-04-02 Vannfrie aripiprazol-krystaller D, fremgangsmåte for fremstilling derav, samt farmasøytisk preparat
NO20081633A NO20081633L (no) 2001-09-25 2008-04-02 Lav hygroskopisk Aripiprazol medikament forbindelse og fremgangsmate for fremstilling derav
NO20091689A NO336679B1 (no) 2001-09-25 2009-04-28 Fremgangsmåte for fremstilling av et fast oralt preparat av granuler, fremgangsmåte for fremstilling av et fast oral preparat, og farmasøytisk fast oralt preparat

Country Status (23)

Country Link
US (20) US20040058935A1 (no)
EP (6) EP1330249B1 (no)
JP (3) JP3760264B2 (no)
CN (16) CN106692151A (no)
AR (2) AR033485A1 (no)
AT (5) ATE467416T1 (no)
AU (1) AU2002334413C1 (no)
BR (1) BR0205391A (no)
CA (6) CA2689051C (no)
CY (1) CY1118195T1 (no)
DE (5) DE60210409T2 (no)
DK (5) DK1330249T3 (no)
ES (5) ES2343220T3 (no)
HU (1) HUP0600141A3 (no)
IL (3) IL153838A0 (no)
MX (1) MXPA03000440A (no)
NO (7) NO328134B1 (no)
PE (1) PE20090124A1 (no)
PL (1) PL225415B1 (no)
PT (5) PT1330249E (no)
SI (4) SI1330249T1 (no)
UA (1) UA84764C2 (no)
WO (1) WO2003026659A1 (no)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
PL212428B1 (pl) * 2002-08-20 2012-09-28 Bristol Myers Squibb Co Kompleks aripiprazolu, preparat farmaceutyczny zawierajacy ten kompleks i jego zastosowanie
AU2003291757A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
MXPA05006857A (es) 2002-12-27 2005-08-18 Otsuka Pharma Co Ltd Derivados de carbostirilo e inhibidores de la recaptacion de serotonina para el tratamiento de desordenes en el humor.
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1480953B2 (en) † 2003-01-09 2010-08-18 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
US20060270683A1 (en) * 2003-04-25 2006-11-30 Lohray Braj B Polymorphs of aripiprazole
KR100881046B1 (ko) 2003-05-23 2009-01-30 오쓰까 세이야꾸 가부시키가이샤 기분 장애를 치료하기 위한 카르보스티릴 유도체 및 기분안정화제
US7456181B2 (en) 2003-07-25 2008-11-25 Hetero Drugs Limited Aripiprazole crystalline forms
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
PL1613598T3 (pl) 2003-12-16 2012-03-30 Teva Pharma Sposób wytwarzania krystalicznych form aripiprazolu
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
EP1765782A1 (en) 2004-02-05 2007-03-28 Teva Pharmaceutical Industries Ltd Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril
WO2005077904A1 (en) * 2004-02-05 2005-08-25 Teva Pharmaceutical Industries, Ltd. Process for preparing aripiprazole
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2006030446A1 (en) * 2004-09-13 2006-03-23 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
DE602004014041D1 (de) 2004-10-08 2008-07-03 Suven Life Sciences Ltd Verfahren zur herstellung von aripiprazol, und entsprechende zwischenprodukte und deren herstellung
CN100338038C (zh) * 2004-10-14 2007-09-19 重庆医药工业研究院有限责任公司 阿立派唑的新晶型及其制备方法
WO2006053780A1 (en) 2004-11-18 2006-05-26 Synthon B.V. Crystalline aripiprazole solvates
WO2006053781A1 (en) * 2004-11-18 2006-05-26 Synthon B.V. Process of making crystalline aripiprazole
EP1844036B1 (en) * 2005-01-27 2015-09-23 Sandoz Ag Process for the preparation of aripiprazole
EP1686117A1 (en) * 2005-01-27 2006-08-02 Sandoz AG Polymorph and solvates of aripiprazole
EP1858514B1 (en) 2005-03-17 2014-11-26 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
WO2006097343A1 (en) † 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline type ii aripiprazole
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP1879865A1 (en) * 2005-04-15 2008-01-23 Medichem S.A. Syntheses and preparations of polymorphs of crystalline aripiprazole
CN100432053C (zh) * 2005-06-07 2008-11-12 上海医药工业研究院 阿立哌唑晶型及其制备方法
HUP0500683A3 (en) * 2005-07-14 2009-03-30 Egis Gyogyszergyar Nyilvanosan New arylpiprazole salts for producing pharmaceutical composition
WO2007011349A1 (en) * 2005-07-15 2007-01-25 Teva Pharmaceutical Industries Ltd. Novel granulation process and granulate produced therefrom
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
JP2008521835A (ja) 2005-09-29 2008-06-26 テバ ファーマシューティカル インダストリーズ リミティド 無水アリピプラゾールフォームｉｉの調製方法
CZ299485B6 (cs) * 2005-10-11 2008-08-13 Zentiva, A. S. Zpusob výroby aripiprazolu
BRPI0608185A2 (pt) * 2005-12-22 2009-11-17 Teva Pharma processo para redução do tamanho de partìcula de aripiprazol
PT1808164E (pt) * 2006-01-05 2009-03-17 Teva Pharma Método de granulação húmida para a preparação de composições farmacêuticas de aripiprazole
PT1808165E (pt) * 2006-01-05 2009-06-09 Teva Pharma Formulações secas de aripiprazole
TWI394753B (zh) 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
EP1880714A1 (en) * 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
TR200604349A2 (tr) 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
WO2008059518A2 (en) * 2006-09-28 2008-05-22 Cadila Healthcare Limited Process for preparing crystalline aripiprazole
WO2008051541A2 (en) * 2006-10-24 2008-05-02 Cambrex Charles City, Inc. Process for preparing anhydrous aripirazole type i
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
AU2008268222B2 (en) * 2007-06-25 2013-12-12 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure
JP4879349B2 (ja) 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
PL2082735T3 (pl) 2008-01-23 2011-05-31 Helm Ag Amorficzny arypiprazol i sposób jego wytwarzania
WO2010079506A2 (en) 2008-06-23 2010-07-15 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of aripiprazole
EP2233471A1 (en) 2009-02-06 2010-09-29 Adamed Sp. z o.o. A salt of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4.dihydro-2(1h)-quinolinone with 5-sulfosalicylic acid and its preparation process
WO2010106551A2 (en) * 2009-03-09 2010-09-23 Neuland Laboratories Ltd. A process for the manufacture of pure anhydrous aripiprazole form b
EP2238976B1 (en) 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
CA2773003A1 (en) 2009-09-15 2011-03-24 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
CN102372672B (zh) * 2010-08-24 2014-06-04 重庆圣华曦药业股份有限公司 低吸湿性阿立哌唑晶体iv、制备方法及其应用
CN101948426A (zh) * 2010-09-13 2011-01-19 浙江华海药业股份有限公司 一种制备阿立哌唑晶型b的新方法
JP2012121850A (ja) * 2010-12-09 2012-06-28 Otsuka Pharmaceut Co Ltd アリピプラゾールの経口速溶性組成物
CN102060763B (zh) * 2010-12-27 2012-11-14 齐鲁制药有限公司 微粉型阿立哌唑晶型ⅰ或ⅱ的制备方法
RU2757859C2 (ru) 2011-03-18 2021-10-21 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбитана
WO2012131451A1 (en) 2011-03-30 2012-10-04 Jubilant Life Sciences Limited Process for producing aripiprazole in anhydrous type i crystals
KR101340214B1 (ko) 2011-03-31 2013-12-10 주식회사 대웅제약 무수 아리피프라졸 ⅱ형 결정의 제조방법
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
JP6034377B2 (ja) * 2011-06-27 2016-11-30 シャンハイ チョンシ ファーマシューティカル コーポレイション アリピプラゾール医薬製剤及びその調製方法
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
CN103172563B (zh) * 2011-12-26 2015-03-25 北京京卫燕康药物研究所有限公司 小粒径的晶型i阿立哌唑的工业化制备
CN102584858B (zh) * 2011-12-31 2014-11-12 广州医药工业研究院 乳酸左旋尤利沙星晶体及其制备方法和用途
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
CA2867123C (en) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
WO2014002553A1 (ja) 2012-06-29 2014-01-03 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
KR101372840B1 (ko) * 2012-08-02 2014-03-12 주식회사 에스텍파마 무수 아리피프라졸 결정의 제조방법
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
JP2014114243A (ja) * 2012-12-11 2014-06-26 Ohara Yakuhin Kogyo Kk 安定な固形製剤の製造方法
CN107129467A (zh) * 2013-03-26 2017-09-05 江苏恩华药业股份有限公司 阿立哌唑结晶b
AU2014260863A1 (en) 2013-04-30 2015-11-05 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
US9051268B2 (en) * 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150093441A1 (en) * 2013-09-30 2015-04-02 Otsuka Pharmaceutical Co., Ltd Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
EP3065700A1 (en) 2013-11-07 2016-09-14 Synthon B.V. Orodispersible pharmaceutical compositions comprising aripiprazole
WO2015143145A1 (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US9859607B2 (en) * 2014-08-18 2018-01-02 Samsung Electronics Co., Ltd Antenna of electronic device
ES2994850T3 (en) * 2014-08-25 2025-02-03 Alkermes Pharma Ireland Ltd Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
JP6023770B2 (ja) * 2014-10-01 2016-11-09 株式会社パーマケム・アジア アリピプラゾール無水物ｂ形結晶の製造方法
US10496213B2 (en) * 2015-02-27 2019-12-03 Tactual Labs Co. Alterable ground plane for touch surfaces
US20180155290A1 (en) * 2015-05-08 2018-06-07 Davuluri Ramamohan Rao Improved Process for the Preparation of Aripiprazole with Reduced Particle Size
JP6071083B2 (ja) * 2015-06-12 2017-02-01 大原薬品工業株式会社 安定性が改善された、アリピプラゾールを含有する散剤
JP2015172084A (ja) * 2015-07-06 2015-10-01 大塚製薬株式会社 アリピプラゾールの経口速溶性組成物
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
WO2017139971A1 (zh) * 2016-02-19 2017-08-24 诺瑞特国际药业股份有限公司 阿立哌唑的新晶型
TWI665194B (zh) * 2016-02-19 2019-07-11 諾瑞特國際藥業股份有限公司 阿立哌唑的新晶型
US20190070174A1 (en) * 2016-03-10 2019-03-07 The Regents Of The University Of Michigan Methods of treating neurodegenerative diseases
CN110088105B (zh) 2016-12-16 2022-03-18 詹森药业有限公司 Jak家族激酶的小分子抑制剂
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP6572257B2 (ja) * 2017-05-16 2019-09-04 大塚製薬株式会社 アリピプラゾールの経口速溶性組成物
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
CN110128337A (zh) * 2019-06-10 2019-08-16 岳阳新华达制药有限公司 一种阿立哌唑晶型b的制备方法
KR102128883B1 (ko) 2019-10-02 2020-07-01 (주)삼화바이오팜 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법
WO2021201239A1 (en) 2020-04-01 2021-10-07 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
WO2024225441A1 (en) 2023-04-26 2024-10-31 Otsuka Pharmaceutical Co., Ltd. Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole
CN117309825B (zh) * 2023-11-30 2024-04-09 四川蜀道建筑科技有限公司 一种透光检测亚甲蓝mb值的设备
CN118878462A (zh) * 2024-06-12 2024-11-01 青岛科技大学 一种药物微晶水中制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62149664A (ja) 1978-03-30 1987-07-03 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体の製造法
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS55127371A (en) 1980-02-14 1980-10-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4771053A (en) 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5162375A (en) * 1988-05-06 1992-11-10 Beecham Group P.L.C. Treatment of neuronal degeneration with 5HT1A agonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
ES2070151T3 (es) * 1988-08-10 1995-06-01 Otsuka Pharma Co Ltd Agentes cardiotonicos.
US5200410A (en) * 1988-09-20 1993-04-06 Troponwerke Gmbh & Co. Medicaments for the treatment of cerebral apoplexy
DE3831888A1 (de) 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
FR2637591B1 (fr) * 1988-10-11 1992-10-23 Synthelabo Derives de quinoleinone, leur preparation et leur application en therapeutique
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5073377A (en) * 1988-11-03 1991-12-17 Miles Inc. Method of preparing oral dosage forms with a granulating composition
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
WO1992010200A1 (en) 1990-12-14 1992-06-25 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
CA2067475C (en) * 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
WO1992020655A1 (en) 1991-05-20 1992-11-26 The Upjohn Company Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
DE4135551A1 (de) 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
US5292766A (en) 1992-03-25 1994-03-08 Eli Lilly And Company Method for improving primary memory and/or learning
AU5446894A (en) 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2506547B2 (ja) 1993-06-16 1996-06-12 ミナミ産業株式会社 豆腐のパック詰め装置
JP2959615B2 (ja) 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH07247271A (ja) * 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
US5663178A (en) * 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
US5504093A (en) * 1994-08-01 1996-04-02 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
JP2987484B2 (ja) 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
JPH0940648A (ja) 1995-08-02 1997-02-10 Yamanouchi Pharmaceut Co Ltd 新規な８−（２−アミノアルコキシ）キノリン誘導体
US5766748A (en) 1995-11-30 1998-06-16 Mitsui Chemicals, Inc. Stretched film of lactic acid-based polymer
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
HU229057B1 (en) 1996-05-07 2013-07-29 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
EP1014977A1 (en) 1996-08-22 2000-07-05 Glaxo Group Limited Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes
WO1998008817A1 (en) 1996-08-27 1998-03-05 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
CN1289333A (zh) 1998-02-03 2001-03-28 美国家用产品公司 用作血清素－1a受体激动剂的噁唑衍生物
JP2001089128A (ja) * 1998-04-10 2001-04-03 Asahi Glass Co Ltd 球状シリカ粒子の製造方法
CA2327477A1 (en) 1998-04-13 1999-10-21 James Albert Nelson 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
EP1076647A2 (en) * 1998-04-29 2001-02-21 American Home Products Corporation Antipsychotic indolyl derivatives
JPH11335286A (ja) 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
US20030027817A1 (en) * 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
KR20020068404A (ko) 2000-01-19 2002-08-27 악조 노벨 엔.브이. 미르타자핀을 포함하는, 우울증 및 관련 장애 치료용 약물조합물
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
JP4197088B2 (ja) 2000-06-05 2008-12-17 電気化学工業株式会社 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
JP2004517112A (ja) 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
DK1397145T3 (da) 2001-06-19 2007-01-02 Norbert Mueller Anvendelse af COX-2-inhibitorer til behandling af schizophrenia eller tics-lidelser
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
KR100881046B1 (ko) 2003-05-23 2009-01-30 오쓰까 세이야꾸 가부시키가이샤 기분 장애를 치료하기 위한 카르보스티릴 유도체 및 기분안정화제
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
JP2009542765A (ja) * 2006-07-12 2009-12-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 結晶性ネモルビシン塩酸塩
US9149434B2 (en) 2007-12-03 2015-10-06 Tomita Pharmaceutical Co., Ltd. Core particle for pharmaceutical preparation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament

Also Published As

Publication number Publication date
CA2688934A1 (en) 2003-04-03
JP2003212852A (ja) 2003-07-30
CN101792415A (zh) 2010-08-04
PL225415B1 (pl) 2017-04-28
US8580796B2 (en) 2013-11-12
US20190225584A1 (en) 2019-07-25
IL153838A (en) 2008-04-13
PT1419776E (pt) 2010-04-28
ATE465737T1 (de) 2010-05-15
CA2689051C (en) 2011-03-08
CN101579344B (zh) 2012-05-30
AU2002334413C1 (en) 2021-08-12
EP1927356A1 (en) 2008-06-04
EP1927356B1 (en) 2010-04-28
US20070212421A1 (en) 2007-09-13
NO20081626L (no) 2003-01-17
CN101434574B (zh) 2011-12-14
CN101423492B (zh) 2013-08-28
EP1927355A1 (en) 2008-06-04
NO20030247L (no) 2003-01-17
US20070203152A1 (en) 2007-08-30
US20070202181A1 (en) 2007-08-30
CA2688915C (en) 2011-02-01
CN101579343A (zh) 2009-11-18
CN101434575A (zh) 2009-05-20
US20120000998A1 (en) 2012-01-05
EP1419776A3 (en) 2004-06-16
DE60236229D1 (de) 2010-06-10
DK1927357T3 (da) 2010-08-16
ES2343220T3 (es) 2010-07-26
ES2343602T3 (es) 2010-08-04
CN1817882A (zh) 2006-08-16
NO336263B1 (no) 2015-07-06
EP1927357A2 (en) 2008-06-04
US20140030523A1 (en) 2014-01-30
SI1927356T1 (sl) 2010-07-30
SI1330249T1 (sl) 2006-10-31
SI1927355T1 (sl) 2010-07-30
EP1419776A8 (en) 2004-09-01
EP1330249B1 (en) 2006-04-05
NO336264B1 (no) 2015-07-06
CN106692151A (zh) 2017-05-24
US20120316179A1 (en) 2012-12-13
US20070203151A1 (en) 2007-08-30
HUP0600141A3 (en) 2008-03-28
US20200123110A1 (en) 2020-04-23
US20120315302A1 (en) 2012-12-13
CA2689052C (en) 2011-02-15
JP3760264B2 (ja) 2006-03-29
US8399469B2 (en) 2013-03-19
DK1927355T3 (da) 2010-07-19
CA2688915A1 (en) 2003-04-03
NO336679B1 (no) 2015-10-19
ES2343179T5 (es) 2017-10-19
DE60210409D1 (de) 2006-05-18
US20040058935A1 (en) 2004-03-25
DE60236383D1 (de) 2010-06-24
CA2689052A1 (en) 2003-04-03
US20120016123A1 (en) 2012-01-19
NO336262B1 (no) 2015-07-06
EP1925308B1 (en) 2016-08-31
US20210395204A1 (en) 2021-12-23
IL188455A0 (en) 2008-03-20
DK1927356T3 (da) 2010-07-26
PT1927357E (pt) 2010-06-08
PT1330249E (pt) 2006-06-30
CA2689051A1 (en) 2003-04-03
SI1419776T2 (sl) 2017-12-29
MXPA03000440A (es) 2003-10-06
US20160251315A1 (en) 2016-09-01
DK1419776T4 (en) 2017-09-04
SI1419776T1 (sl) 2010-07-30
US20150225347A1 (en) 2015-08-13
US8017615B2 (en) 2011-09-13
WO2003026659A1 (en) 2003-04-03
CN101434574A (zh) 2009-05-20
NO20091689L (no) 2003-01-17
US20070203150A1 (en) 2007-08-30
NO20081632L (no) 2003-01-17
ATE464050T1 (de) 2010-04-15
CN101434573A (zh) 2009-05-20
NO328134B1 (no) 2009-12-14
EP1419776B1 (en) 2010-04-14
EP1419776B2 (en) 2017-07-19
BR0205391A (pt) 2003-07-29
US8901303B2 (en) 2014-12-02
US8642760B2 (en) 2014-02-04
AR033485A1 (es) 2003-12-26
CN101423492A (zh) 2009-05-06
DE60235995D1 (de) 2010-05-27
US20140309236A1 (en) 2014-10-16
CN106420640A (zh) 2017-02-22
NO20081627L (no) 2003-01-17
CN101574348A (zh) 2009-11-11
JP4614870B2 (ja) 2011-01-19
EP1419776A9 (en) 2004-09-08
JP2004256555A (ja) 2004-09-16
CN101574347A (zh) 2009-11-11
CN101574348B (zh) 2012-02-22
EP1927355B1 (en) 2010-04-28
CY1118195T1 (el) 2017-06-28
IL153838A0 (en) 2003-07-31
ATE465736T1 (de) 2010-05-15
EP1927357B1 (en) 2010-05-12
CA2688934C (en) 2011-05-17
CN106420627A (zh) 2017-02-22
AU2002334413C9 (en) 2015-04-09
DE60236231D1 (de) 2010-06-10
EP1927357A3 (en) 2008-06-11
AU2002334413B2 (en) 2004-11-04
DK1330249T3 (da) 2006-08-07
CN1699346A (zh) 2005-11-23
PE20090124A1 (es) 2009-03-07
US20070213344A1 (en) 2007-09-13
US20120316180A1 (en) 2012-12-13
CN1463191A (zh) 2003-12-24
JP3750023B2 (ja) 2006-03-01
EP1419776A2 (en) 2004-05-19
US8703773B2 (en) 2014-04-22
PT1927355E (pt) 2010-06-11
US8993761B2 (en) 2015-03-31
EP1330249A1 (en) 2003-07-30
UA84764C2 (en) 2008-11-25
US8901130B2 (en) 2014-12-02
ATE467416T1 (de) 2010-05-15
ES2261750T3 (es) 2006-11-16
PT1927356E (pt) 2010-05-24
NO20081633L (no) 2003-01-17
AR056503A2 (es) 2007-10-10
ES2343179T3 (es) 2010-07-26
JP2006070045A (ja) 2006-03-16
CA2688860A1 (en) 2003-04-03
NO336265B1 (no) 2015-07-06
HUP0600141A2 (hu) 2006-05-29
ES2343219T3 (es) 2010-07-26
NO20030247D0 (no) 2003-01-17
CN101579344A (zh) 2009-11-18
CN101574347B (zh) 2012-02-29
US9359302B2 (en) 2016-06-07
PL360900A1 (en) 2004-09-20
DE60210409T2 (de) 2006-11-16
CA2426921C (en) 2011-03-15
CA2426921A1 (en) 2003-04-03
EP1925308A1 (en) 2008-05-28
CN1817882B (zh) 2011-09-07
CN101579343B (zh) 2012-04-18
CN101434573B (zh) 2011-12-07
CN101423493A (zh) 2009-05-06
US7910589B2 (en) 2011-03-22
ATE322269T1 (de) 2006-04-15
US20070213343A1 (en) 2007-09-13
DK1419776T3 (da) 2010-07-05
US10150735B2 (en) 2018-12-11

Similar Documents

Publication Publication Date Title
NO20081631L (no) Lav hygroskopisk Aripiprazol medikament forbindelse og fremgangsmate for fremstilling derav
NO20005535L (no) Pyrazol-derivater som P-38 MAP kinase-inhibitorer
NO992400L (no) Nye substituerte pyrazolderivater
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
NO2005025I1 (no) Krystalinsk ceftiofurfri syre, fremgangsmate for fremstilling av denne, og farmasoytisk preparat
NO991732L (no) Nye heterocyklylmetylsubstituerte pyrazolderivater
NO20045429L (no) Kombinasjon av organiske forbindelser
NO20041879L (no) Polymorf form av rimonabant, fremgangsmate for fremstilling derav og farmasoytisk preparat inneholdende det samme.
HUP0203257A2 (hu) Atorvastatin kalcium polimorf módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
HUP0203333A2 (hu) Eljárás benzimidazolalapú vegyületek stabilizálására
NO20082938L (no) Formuleringer av quinolinoner
NO20045469L (no) (S)-4-amino-5-klor-2-metoksy-N-[I-[ 1-(2-tetrahydrofurylkarbonyl)-4-piperidinylmetyl]-4-piperidinyl]benzamid, fremgangsmate for fremstilling, farmasoytiske sammensetninger inneholdende denne og intermediater derav
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
NO20052676L (no) Polymorfer av bicifadin-saltsyre
HUP0200580A2 (hu) Celecoxib polimorf kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BRPI0407841A (pt) inibidores heterocìclicos de quinase
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
WO2003051838A3 (en) Protein kinase inhibitors
NO20064986L (no) Krystallin Pyrazolderivater
WO2004056832A3 (en) Epothilone derivatives
NO20041732L (no) Anvendelse av irbesartan for fremstilling av medikamenter som anvendes for a forhindre eller behandle pulmonal hypertensjon
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
PH12014500782A1 (en) Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
RS53474B (en) PROCEDURE FOR OBTAINING CRYSTAL FORM AND OLANZAPINE

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees